

Contents

| | |
|---|-----------|
| Preface | ix |
| Abbreviations | xi |
| 1 Introduction | 1 |
| 1.1 Overview | 1 |
| 1.1.1 Endocrine disorders | 2 |
| 1.1.2 Severe combined immunodeficiency disorders | 2 |
| 1.2 Biomacromolecules in the Treatment of Human Disease | 4 |
| 2 Endogenous Peptides and Proteins | 7 |
| 2.1 Overview | 7 |
| 2.2 Isolation from Natural Tissues and Fluids | 11 |
| 2.3 Synthesis and Semi-Synthesis | 12 |
| 2.3.1 Peptide synthesis | 12 |
| 2.4 Gene Cloning | 26 |
| 2.4.1 Growth hormone | 37 |
| 2.5 Transgenic Procedures | 39 |
| 2.6 Examples of Direct Replacement Strategy | 40 |
| 2.6.1 Insulin | 40 |
| 2.6.2 The fibrin and fibrinolytic cascades | 46 |
| 3 Modification of Endogenous Peptides and Proteins | 55 |
| 3.1 Overview | 55 |
| 3.2 Peptide Mimetics | 56 |
| 3.2.1 Mimetics based on luteinizing hormone-releasing hormone | 62 |
| 3.2.2 Mimetics based on somatostatin | 64 |
| 3.3 Chemical Modification of Proteins | 67 |
| 3.3.1 Immunoassays | 69 |

| | |
|---|------------|
| 3.3.2 Modification with synthetic polymers | 72 |
| 3.3.3 Modification of enzyme active sites | 74 |
| 3.4 Protein Engineering | 75 |
| 3.4.1 Site-directed mutagenesis | 76 |
| 3.4.2 Chimeric toxins | 78 |
| 3.4.3 Chimeric and humanized antibodies | 80 |
| 3.4.4 The single-chain Fv | 85 |
| 3.4.5 Phage display | 87 |
| 4 The Immune System | 95 |
| 4.1 Overview | 95 |
| 4.2 The Antibody-Mediated Response | 95 |
| 4.2.1 Polyclonal antibodies | 95 |
| 4.2.2 Monoclonal antibodies | 99 |
| 4.3 Vaccines | 107 |
| 4.3.1 Hepatitis B vaccine | 108 |
| 4.3.2 Approaches to an HIV vaccine | 110 |
| 4.4 The Cell-Mediated Immune Response | 114 |
| 4.4.1 Immunoenhancement | 119 |
| 4.4.2 Immunosuppression | 119 |
| 4.5 Cancer Immunotherapy | 124 |
| 4.5.1 Antibody-mediated immunotherapy | 125 |
| 4.5.2 T-cell-mediated immunotherapy | 128 |
| 5 Oligonucleotides | 135 |
| 5.1 Overview | 135 |
| 5.2 Gene Therapy | 136 |
| 5.2.1 Introduction | 136 |
| 5.2.2 <i>Ex vivo</i> gene delivery | 138 |
| 5.2.3 Clinical applications | 143 |
| 5.3 Antisense Therapy | 151 |
| 5.3.1 Introduction | 151 |
| 5.3.2 Development of an antisense oligonucleotide | 154 |
| 5.3.3 Clinical studies | 163 |
| 5.4 Ribozymes | 164 |
| 6 Oligosaccharides | 169 |
| 6.1 Overview | 169 |
| 6.2 Oligosaccharide Synthesis | 171 |
| 6.3 Heparin | 178 |
| 6.4 Glycoproteins | 179 |
| 6.4.1 Blood group oligosaccharides | 180 |

| | |
|--|------------|
| 6.5 Polysaccharide Bacterial Vaccines | 182 |
| 6.6 Approaches to Carbohydrate-Based Cancer Vaccines | 182 |
| Appendix | 191 |
| A.1 Amino Acids and Peptides | 191 |
| A.1.1 Abbreviations and structural representations | 191 |
| A.1.2 Secondary structures | 193 |
| A.2 Oligonucleotides, DNA and RNA | 196 |
| A.3 Carbohydrates | 199 |
| Glossary | 203 |
| Index | 215 |

bioRxiv preprint doi: <https://doi.org/10.1101/2023.05.10.537000>; this version posted May 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [aCC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).